The life sciences industry is facing a perfect storm of converging issues. The “patent cliff” and increasing demands of transforming scientific research and discoveries into marketable products have intensified the need to identify viable opportunities quickly. Sourcing funds for R&D, pre-clinical and early-phase drug development, and necessary investment in evolving technologies is particularly difficult considering efforts to reduce the cost of healthcare and related impacts on profits. Many life science companies have evaluated mergers, acquisitions or strategic alliances as options to address these opportunities and challenges.
BDO’s Life Sciences practice provides responsive guidance to pharmaceutical, biotech and medical device manufacturers of all sizes and at every stage of development. From understanding the complexities of collaborative R&D and licensing agreements and R&D tax credits to transaction advisory, and merger and acquisition due diligence, BDO’s services encompass more than traditional audit, tax, risk advisory, or consulting. With industry knowledge and experienced, service-driven professionals, we can help you address the diverse business issues affecting the industry.